Navigation Links
First Warning Systems and Unicorp Biotech International Strategic Partner Letter of Intent Signed Breast Cancer Early Detection

RENO, Nev., Dec. 12, 2012 /PRNewswire/ -- First Warning Systems, Inc. announced a Letter of Intent with Budapest, Hungary, European Union based medical products marketing partner, UniCorp Biotech. "We look forward to productive developments regarding the regulatory advise, marketing and distribution resources of UniCorp Biotech", says Jim Holmes, Chairman and CEO of First Waning Systems. "The Letter of Intent outlines a mutually beneficial process for defining how the capabilities of UniCorp Biotech can partner with First Warning", adds Dr. Laszlo Horvath, CEO.

"We are planning for the CE Mark process early in 2013 to be followed by clinical validation and market entry of the First Warning Systems in select European markets", says Matt Benardis, First Warning Operations Manager. "Discussions with Dr. Horvath regarding UniCorp Biotech services to expedite certification and time-to-market have been encouraging", adds Benardis.

About First Warning Systems Process
Temperature readings of breast tissue create a dynamic cell chaos profile using 9,600 points of dynamic data which are correlated to dysfunctional circadian genes. Multiple bioinformatics algorithms compare the circadian gene protein profiles to identify breast tissue abnormalities at different stages of development of disturbed breast cancerous cells. FWS delivers a report to the primary care physician with industry leading 90% accuracy. The FWS process is the only detection process that identifies abnormalities before a tumor presents and can be used by a primary care physician.

About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS's principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive development, manufacturing and marketing worldwide license from Lifeline, to commercialize the intellectual property. The FWS product line is a device and process that detects breast tissue abnormalities leading to health risk assessment and management and potentially, breast cancer. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS product. FWS is preparing to apply for a Euro CE Mark to market in the UK, EU and Russia markets. See FWS' video, "Breast Cancer Tumor Progression" at For more information, contact: Abbi Whittaker, The Abbi Agency. (775) 323-2977,

About Unicorp Biotech
UniCorp Biotech was founded at the turn of the century. The owners desire to play a key role in the changing health care system of Europe in the area of quick and easy home access. Our company also manages (preparations, ethical permissions, monitoring) CRO projects within and outside of the European Union. We have the privilege to welcome among our customers many multinational companies acting in health care and distribution, such as Merck-Serono, Alexion, Gedeon Richter, PhamaNord, PhoenixPharma, HungaroPharma, Krka, Yamanouchi, Pliva, Tesco, Rossmann, Schlecker, Hungarian Military, National Police Headquarters. Our products are available in most pharmacies throughout Hungary and in some CEE countries. Since January of 2006, we have been the official Hungarian representatives of the Berlin-based Bayer Dermatology. UniCorp Biotech also provides information and preventive help for women, infants and Hungarians needing to be more informed, & & provide assistance to those dealing with drug or other dependencies. For more information, contact: Dr. Laszlo Horvath, CEO, UniCorp Biotech Kft, H-1126 Budapest, Toth Lorincu.41., Hungary, Tel.: +36-1-393-5050, Fax: +36-1-393-5055.

SOURCE First Warning Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
2. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
3. Karmanos Cancer Center first in Midwest to offer latest Molecular Breast Imaging
4. China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
5. First Effective Treatment For Traumatic Brain Injury Reported by Institute of Neurological Recovery, Even Years After Injury
6. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
7. First noiseless single photon amplifier
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
9. Elektas Monaco System Used for First Time to Create VMAT Plan for Delivery on Varian Treatment System
10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
11. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
Post Your Comments:
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... San Francisco, CA (PRWEB) , ... November 25, ... ... leading microbial genomics company uBiome, were featured on AngelList early in their initial ... by launching an AngelList syndicate for individuals looking to make early stage investments ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
Breaking Biology News(10 mins):